Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis
Por:
Mateos, L, Jiménez-Fonseca, P, Gallego, J, Lecumberri, A, Custodio, A, de Castro, EM, San Gil, RH, Montes, AF, Limon, ML, Vidal-Tocino, R, Cano, JM, Robles, JL, Gil, M, Eyzaguirre, DA, Zafra, GM, Mérida-García, AJ, Fernández, AF, Fernández, PR, Hierro, C, Riesco, MC, Araque, MG, Martín, MR, Pimentel, P, Visa, L, Cerdá, P, Granja, M, Blanco, ABR, Gutiérrez, L and Carmona-Bayonas, A
Publicada:
8 feb 2026
Ahead of Print:
1 nov 2025
Resumen:
BackgroundTranslating trial findings to real-world cure rates for resectable oesophageal and gastroesophageal junction (GEJ) adenocarcinoma is critical. Standard endpoints like disease-free survival (DFS) may not distinguish durable cures from delayed recurrences.MethodsThis analysis of the AGAMENON-SEOM registry (NCT04958720) compared perioperative chemotherapy versus neoadjuvant chemoradiotherapy (nCRT). We estimated cure rates and analysed DFS and overall survival (OS) using mixture cure models and Cox proportional hazards models.ResultsIn 500 patients, perioperative FLOT improved DFS (HR 0.60; p = 0.01) and OS (adjusted HR 0.63; p = 0.015) compared to CROSS-based nCRT. Notably, cure models confirmed a higher cure fraction for FLOT in high-risk subgroups (e.g., stage III, high neutrophil-to-lymphocyte ratio). While platinum-fluoropyrimidine-based nCRT +/- immunotherapy yielded higher R0 and pathological complete response rates, its estimated cure rate was comparable to FLOT, both overall and across all subgroups.ConclusionCure is an informative endpoint in localised oesophageal cancer. In this registry analysis, perioperative FLOT was associated with higher cure rates than CROSS, particularly in high-risk subgroups. Exploratory findings suggest that alternative neoadjuvant strategies, such as those incorporating ICIs or FOLFOX, warrant further investigation.
Filiaciones:
Mateos, L:
Hosp Univ Cent Asturias HUCA, Dept Med Oncol, ISPA, Oviedo, Spain
Univ Valladolid, Valladolid, Spain
Jiménez-Fonseca, P:
Hosp Univ Cent Asturias HUCA, Dept Med Oncol, ISPA, Oviedo, Spain
Gallego, J:
Hosp Gen Univ Elche, Dept Med Oncol, Elche, Spain
Lecumberri, A:
Hosp Univ Navarra, Dept Med Oncol, Navarrabiomed Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain
Custodio, A:
Hosp Univ La Paz, Dept Med Oncol, CIBERONC CB16-12-00398, Madrid, Spain
de Castro, EM:
Hosp Univ Marques Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
San Gil, RH:
Hosp Univ Canarias, Dept Med Oncol, San Cristobal la Laguna, Tenerife, Spain
Montes, AF:
Complejo Hosp Univ Ourense, Dept Med Oncol, Orense, Spain
Limon, ML:
Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
Vidal-Tocino, R:
Complejo Asistencial Univ Salamanca IBSAL, Dept Med Oncol, Salamanca, Spain
Cano, JM:
Hosp Gen Univ Ciudad Real, Dept Med Oncol, Ciudad Real, Spain
Robles, JL:
Univ Murcia, Hosp Univ Morales Meseguer, Dept Med Oncol, IMIB, Murcia, Spain
Gil, M:
Hosp Clin Univ Valencia, Dept Med Oncol, CIBERONC CB16-12-0035, Valencia, Spain
Eyzaguirre, DA:
Hosp Univ Vall dHebron, Dept Med Oncol, VHIO, Barcelona, Spain
Zafra, GM:
Hosp Univ Virgen Arrixaca, Dept Med Oncol, Murcia, Spain
Mérida-García, AJ:
Complejo Asistencial Zamora, Dept Med Oncol, Zamora, Spain
Fernández, AF:
Complejo Hosp Univ Pontevedra, Dept Med Oncol, Pontevedra, Spain
Fernández, PR:
Hosp Univ Parc Tauli, Inst Recerca & Innovacio Parc Tauli I3PT CERCA, Dept Med Oncol, Sabadell, Spain
:
Inst Catala Oncol ICO Badalona, Dept Med Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona, Spain
Riesco, MC:
Hosp Univ 12 Octubre, Dept Med Oncol, IMAS12, Madrid, Spain
Araque, MG:
Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain
Martín, MR:
Complejo Asistencial Univ Palencia, Dept Med Oncol, Palencia, Spain
Pimentel, P:
Hosp Univ Santa Lucia, Dept Med Oncol, Cartagena, Spain
Visa, L:
Hosp El Mar, Dept Med Oncol, Barcelona, Spain
Cerdá, P:
Hosp Santa Creu I St Pau, Dept Med Oncol, Barcelona, Spain
Granja, M:
Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid, Spain
Blanco, ABR:
Hosp Univ Toledo, Dept Med Oncol, Toledo, Spain
Gutiérrez, L:
Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
Carmona-Bayonas, A:
Univ Murcia, Hosp Univ Morales Meseguer, Dept Med Oncol, IMIB, Murcia, Spain
Green Submitted, hybrid
|